Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.84 |
| ▸ | CHUK | O15111 | 6/20 | 0.84 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688455 | 0.92 | IKBKB (0.98) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4685409 | 0.91 | IKBKB (0.84) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4690878 | 0.91 | IKBKB (1.00) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4685590 | 0.87 | IKBKB (0.90) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4685414 | 0.85 | IKBKB (0.82) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4688583 | 0.85 | IKBKB (0.88) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4687355 | 0.83 | IKBKB (0.85) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4690886 | 0.83 | IKBKB (0.75) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4688558 | 0.82 | IKBKB (0.84) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4687440 | 0.82 | IKBKB (0.80) | IKBKBCHUKAURKAFLT3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | claimed |
| EP-1703905-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | claimed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1703905-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | IKBKB 2/4885CHUK 6/4885AURKA 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.